Molecular pathology of lung cancer: key to personalized medicine.

摘要: The majority of lung adenocarcinoma patients with epidermal growth factor receptor- (EGFR) mutated or EML4-ALK rearrangement-positive tumors are sensitive to tyrosine kinase inhibitors. Both primary and acquired resistance in a significant number those these therapies remains major clinical problem. specific molecular mechanisms associated inhibitor not fully understood. Clinicopathological observations suggest that alterations involving so-called 'driver mutations' could be used as markers aid the selection most likely benefit from targeted therapies. In this review, we summarize recent developments have been EGFR-targeted therapy adenocarcinomas. Understanding may provide new treatment avenues improve current algorithms.